Castle Biosciences, Inc. (CSTL) vs Veracyte, Inc. (VCYT)
- Castle Biosciences, Inc. CSTL 31.96 −5.44%
- Veracyte, Inc. VCYT 43.12 −2.86%
Castle Biosciences, Inc. and Veracyte, Inc. are both Diagnostics & Research companies. Veracyte, Inc. is the larger, with a market value of $3.6B against $1.0B — 3.5× the size. Castle Biosciences, Inc. has negative trailing earnings, so its P/E is not meaningful; Veracyte, Inc. trades at 29.9×. Veracyte, Inc. grew revenue faster over the last twelve months: 17.3% against 3.18%. Veracyte, Inc. has the higher net margin (20.4% vs −5.43%) and the higher return on invested capital (7.32% vs −9.40%). Across the 18 metrics below, Veracyte, Inc. leads on 13 and Castle Biosciences, Inc. on 5.
Valuation
Profitability
| Metric | CSTL | VCYT | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | 77.26% | 71.71% | 50.89% |
| Operating margin | (8.99%) | 18.82% | (8.57%) |
| Net margin | (5.43%) | 20.37% | (6.37%) |
| Free cash flow margin | (0.13%) | 29.54% | 0.00% |
| Return on equity | (4.20%) | 8.77% | (2.92%) |
| Return on assets | (3.51%) | 8.09% | (6.71%) |
| Return on invested capital | (9.40%) | 7.32% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack